Shire
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Shire sits in the top decile of US sponsors by registered trial count (#133 of 15,742 sponsors by registered trial count).
Shire: 245 sponsored US clinical trials, 1 recruiting.
Shire sponsors 245 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 212 completed. 118 of these trials are in Phase 3-4 (later-stage) and 108 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 6 trials.
Top-decile sponsor footprint
Shire ranks in the top decile of sponsors by registered trial count (#133 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
212 of 242 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (87.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
245 total, page 1 of 5
Gaucher Disease Outcome Survey (GOS)
NCT03291223
A Study of Intrathecal SHP611 in Children With Metachromatic Leukodystrophy
NCT03771898
Registry for Participants With Short Bowel Syndrome
NCT01990040
A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor
NCT04444895
A Study to Evaluate the Bioavailability of Teduglutide Administered Subcutaneously by Syringe Injection Versus Pen Injector in Healthy Adult Participants
NCT04465396
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Maribavir Administered in Healthy Japanese Participants Compared With Matched, Healthy, Non-Hispanic, Caucasian Participants and to Assess Dose-Proportionality of 3 Doses of Maribavir in Japanese Participants
NCT04497883
A Study Comparing the Pharmacokinetics and Palatability of Two Candidate Pediatric Powder-for-Oral-Suspension Formulations of Maribavir to the Current Maribavir Tablet Formulation Administered in Healthy Adult Participants
NCT04131556
A Study of SHP655 (rADAMTS13) in Sickle Cell Disease
NCT03997760
Study of rADAMTS-13 (SHP655) in the Treatment of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
NCT03922308
A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)
NCT04085172
A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Children
NCT04070326
A Study to Determine the Bioavailability of Lanadelumab (SHP643) Administered Subcutaneously With the Prefilled Syringe and the Autoinjector in Healthy Adult Volunteer Participants.
NCT03918239
A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America
NCT03845400
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending, Subcutaneous, Single and Multiple Doses of SHP681 (Glucagon-like Peptide-2 [GLP-2] Analog-Fc Fusion) in Healthy Adult Participants
NCT03859323
Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of SPD422 (Anagrelide Hydrochloride) in Healthy Adult Participants
NCT03866434
Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)
NCT03627091
Safety and Efficacy Study of rhPTH(1-84) in Subjects With Hypoparathyroidism
NCT03364738
Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 305)
NCT03559517
Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 306)
NCT03566823
An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis
NCT03290781
Safety, Tolerability and Pharmacokinetics of SHP465 in Children Aged 4 to 5 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT03327402
A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
NCT03283085
Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis
NCT03259334
A Study to Learn if Recombinant Human Parathyroid Hormone [rhPTH(1-84)] Can Improve Symptoms and Metabolic Control in Adults With Hypoparathyroidism (BALANCE)
NCT03324880
Study of Lanadelumab in Healthy Japanese and Matched Caucasian Adult Subjects
NCT03401671
Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
NCT03325894
Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years
NCT03325881
Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis
NCT03259308
Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Participants With Eosinophilic Esophagitis (EoE)
NCT03245840
Safety and Efficacy Study in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
NCT03260205
Study of rhPTH(1-84) in Japanese Healthy Subjects Compared With Matched Caucasian Healthy Adult Subjects
NCT03150108
Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma
NCT03131167
A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants
NCT02927067
Study to Assess the Blood Concentrations and Actions of Recombinant Human Parathyroid Hormone (rhPTH [1-84]) When Given Once and Twice Daily to Participants With Hypoparathyroidism
NCT02781844
Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Placebo
NCT03004924
Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Placebo
NCT02998554
Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Povidone-iodine (PVP-I) and Placebo
NCT02998541
Observational Natural History Study of Autosomal Dominant Retinitis Pigmentosa (adRP)
NCT02926092
Long-term Safety and Efficacy Study of Teduglutide in Pediatric Participants With Short Bowel Syndrome (SBS)
NCT02954458
Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
NCT02931539
Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed the TED-C13-003 Study
NCT02949362
A Study of Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) in Hypoparathyroidism
NCT02910466
Study of SHP620 (Maribavir) in Healthy Adults
NCT02775240
Study of the Effect of Velaglucerase Alfa (VPRIV®) on Bone-related Pathology in Treatment-naïve Participants With Type 1 Gaucher Disease
NCT02574286
Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition
NCT02682381
Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
NCT02741596
A Multicenter Study to Evaluate the Efficacy and Safety of Cinryze® for the Treatment of Acute Antibody-mediated Rejection in Participants With Kidney Transplant
NCT02547220
An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE)
NCT02736409
Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
NCT02586805
Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Recombinant Human C1 Esterase Inhibitor in Healthy Adult Subjects
NCT02663687
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 52 |
| Phase 2 | 56 |
| Phase 3 | 98 |
| Phase 4 | 20 |
What is open in the Shire pipeline
1 recruiting of 245 indexed (0% open); 212 completed (87%).
Phase mix: 118 late (III/IV) vs 108 early (I/II) (balanced across stages).
Top condition: Healthy (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Shire: open-pipeline peers nationwide
Peers matched on 245 registered trials and 0% open enrollment, not the therapeutic-area sidebar.
Shire sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 245 trials (± recruiting share)
- University of Cincinnati · 245 trials · 14% recruiting
- State University of New York at Buffalo · 243 trials · 21% recruiting
- Masonic Cancer Center, University of Minnesota · 249 trials · 14% recruiting
- University of Massachusetts, Worcester · 240 trials · 13% recruiting
Sponsors near 0% open enrollment (± trial volume)
- Gynecologic Oncology Group · 1% recruiting · 154 trials
- Mylan Pharmaceuticals · 1% recruiting · 146 trials
- Johnson & Johnson Vision Care · 1% recruiting · 142 trials
- 10xBio · 0% recruiting · 3 trials
Related
What to do with this Shire page
245 registered trials is a research-attention snapshot, not an endorsement of Shire or any single study.
- 1 of Shire's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy is the condition Shire studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Shire pipeline card: 245 registered trials from official public datasets.Report a data error.